M ultiple sclerosis (MS) is an autoimmune and neurodegenerative disorder influenced by genetics, female gender and vitamin D 3 (refs 1-3). Molecular mechanisms demonstrating how gene-gene and gene-environmental interactions combine to regulate disease risk remain largely unknown. Genome-wide association studies (GWAS) of common polymorphisms have identified only a proportion of the genetic variation responsible for familial disease clustering in complex trait diseases such as MS 4 , leading some to suggest that rare and highly penetrant variants account for the missing heritability [5] [6] [7] [8] . However, rare and highly penetrant variants often display Mendelian type inheritance and are relatively insensitive to environmental influences (for example, cystic fibrosis). An alternative is epistatic interactions 9 between multiple independent alleles and the environment that affect a common biochemical pathway, whereby each factor has only a minor genetic and/or biological effect, but when combined results in severe deficiencies. Consistent with this, MS concordance rates in monozygotic twins are only ~30% (ref. 10) , despite recent evidence that discordant twins do not harbour significant sequence differences in their genome, epigenome and transcriptome 11 . This implies direct environmental impact on genetic risk.
Virtually all cell surface and secreted proteins in metazoans are modified by co-and/or post-translational addition of complex carbohydrates in the endoplasmic reticulum/Golgi secretory pathway 12, 13 , providing information encoding distinct from the genome 14 . Unlike DNA/RNA/protein, production of complex carbohydrates is not template driven, but rather is controlled by the activity of endoplasmic reticulum/Golgi enzymes and metabolic supply of their substrates. The branching and number of N-glycans per protein molecule cooperate to regulate binding to galectins, forming a molecular lattice at the cell surface that controls the concentration and endocytosis of surface glycoproteins 14 . N-Glycan number is gene-encoded while branching is conditional to activity of the Golgi α-mannosidases, N-acetylglucosaminyltransferases I, II, IV and V (Mgat1, 2, 4 and 5) and hexosamine pathway production of the substrate uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) 15, 16 ( Fig. 1a) . In mice, genetic deficiencies in N-glycan branching promote neurodegeneration, spontaneous inflammatory demyelination, T cell receptor (TCR) clustering/signalling, T helper 1 (T H 1) differentiation and endocytic loss of the growth and autoimmune inhibitor cytotoxic T-lymphocyte antigen 4 (CTLA-4), phenotypes that can be reversed by metabolic supplementation to UDP-GlcNAc biosynthesis [15] [16] [17] [18] [19] [20] [21] . In this study, we investigate whether similar mechanisms are active in MS through detailed biological characterization of known polymorphisms and a unique candidate gene approach. Our data ) and analysed as in d. Genotypes for human cells were IL2RA*TC and IL7RA*CC except for d, which was IL2RA*TT. P values by analysis of variance and the Newman-Keuls Multiple Comparison Test. ***P < 0.001, **P < 0.01 in all panels. Error bars are standard error of triplicate or greater values in all panels.
suggests that N-glycosylation provides the first unifying molecular mechanism in MS, whereby convergent genetic dysregulation is modulated by multiple environmental inputs such as metabolism and sunlight/vitamin D 3 .
Results

IL-2 and IL-7 regulate T cell growth via N-glycan branching.
Interleukin-2 receptor (IL-2R) and interleukin-7 receptor (IL-7R) are members of the common γ chain cytokine receptor family and use signal transduction through Stat5. Recently, genetic alterations in the IL-2 and IL-7 signalling pathways have been implicated in MS 3, 22, 23 . To examine whether these pathways alter N-glycan branching, we used flow cytometry with L-PHA (Phaseolus vulgaris, leukoagglutinin), a plant lectin that binds specifically to β1,6GlcNAc-branched N-glycans, the product of Mgat5 (Fig. 1a ) 18, 24 . Addition of exogenous IL-2 or IL-7 to resting human T cells reduced L-PHA-binding structures (hereafter termed as branching) in CD25 − CD4 + T cells by ~20-30% ( Fig. 1b and Supplementary Fig. S1a ). Analysis of IL-2 and IL-7RA deficient ex vivo CD25 − CD4 + mouse T cells revealed ~50% and > 2-fold increases in branching, respectively, confirming that autocrine IL-2 and IL-7 signalling regulates branching in vivo (Fig. 1c) . As ~15-20% change in L-PHA binding is sufficient to alter T cell function, growth and autoimmune risk 16, 20 , these alterations are highly significant and in the case of IL-7RA deficiency, represents the largest change observed outside of direct manipulation of the Golgi branching pathway. Indeed, addition of exogenous IL-2 or IL-7 both induce ~2-fold increase in the Golgi MGAT1 mRNA as well as ~1.5-3-fold decreases in Golgi MGAT5, MGAT4B, mannosidase II and IIx (MAN2A1, MAN2A2) and mannosidase Ia and b (MAN1A1, MAN1A2; Fig. 1d,e) . These mRNA changes are opposite of that induced by TCR signalling, which enhances branching 25 . Mgat1 has a ~250-fold higher affinity for UDP-GlcNAc than Mgat5 and over expression of Mgat1, particularly in the presence of reduced Mgat4 and Mgat5, decreases branching by limiting UDPGlcNAc supply to Mgat4 and Mgat5 (refs 15, 25) .
T cell activation enhances branching as well as IL-2 and IL-2RA expression; therefore, we next examined the effects of IL-2 and IL-7 signalling in T cell blasts. Exogenous IL-2 enhanced TCR signalling-induced increases in branching in CD25 + CD4 + mouse and human T cell blasts, whereas anti-IL-2 neutralizing antibody, the IL-2RA antagonist Ro26-4550 and/or IL-2 deficiency had the opposite effect ( Fig. 2a and Supplementary Fig. S1b) . Similarly, addition of exogenous IL-7 increased branching in human CD25 + CD4 + T cell blasts, whereas deficiency of IL-7RA limited upregulation of branching in mouse CD25 + CD4 + T cell blasts ( Fig. S1c ). These data are consistent with the ultra-sensitive kinetics of the Golgi branching pathway 15 , in which MGAT1 hyperactivity limits branching in resting T cells with low UDP-GlcNAc and Mgat5 activity, but enhances branching in T cell blasts where UDP-GlcNAc, Mgat5 and mannosidase IIx are enhanced. CD25 is also constitutively expressed by FoxP3 + T regulatory cells; however, IL-2 enhanced branching to a much greater extent in CD25 + FoxP3 − T cell blasts ( Supplementary Fig.  S1d ). Thus, IL-2 and IL-7 co-regulate multiple Golgi genes to reduce branching in resting T cells; but promote branching in T cell blasts.
Cytokine-induced alterations in branching are expected to initially promote TCR-mediated growth 18 , followed by enhanced growth arrest of T cell blasts by increased CTLA-4 surface expression 15 . Indeed, pretreatment of resting human T cells with IL-2 significantly enhanced TCR signalling-mediated upregulation of CD69 in the absence but not presence of N-acetylglucosamine (GlcNAc) and uridine (Fig. 2c) . GlcNAc and uridine enhance branching by increasing UDP-GlcNAc supply to the Golgi 15, 16 , and rescued reductions induced by IL-2 (Fig. 2c inset) . Similarly, analysis of IL7RA − / − Mgat5 − / − double knockout mice revealed that suppression of TCR activation by IL7RA deficiency requires Mgat5 (Fig. 2d) . In CD25 + CD4 + T cell blasts, anti-IL-2 neutralizing antibody and IL-2 deficiency reduced CTLA-4 surface expression (Fig. 2e,f) , the latter reversed by the addition of exogenous IL-2 in the absence but not presence of swainsonine (SW; Fig. 2f ). SW is an inhibitor of Golgi α-mannosidase II/IIx that reduces branching downstream of Mgat1 ( Fig. 1a ) 26 , confirming that IL-2 promotes CTLA-4 surface retention by increasing branching.
IL2RA and IL7RA MS risk alleles reduce MGAT1 and branching.
The IL2RA*T (rs2104286) and IL7RA*C (rs6897932) MS risk alleles are the common alleles in Caucasian populations (frequency ~75%) and are associated with enhanced secretion of soluble receptors (that is, sIL2RA and sIL7RA) that bind cognate cytokines and antagonize signalling ( Supplementary Fig. S2a -c) 22, [27] [28] [29] . Exogenous sIL2RA and sIL7RA/Fc chimera both reduced branching in CD25 + CD4 + T cell blasts, an effect that was additive when combined and rescued by exogenous IL-7 or GlcNAc (Fig. 2a,b ). Blocking IL-2 and IL-7 signalling with sIL2RA and sIL7RA or anti-IL-2 and anti-IL-7 neutralizing antibodies both reduced MGAT1 mRNA in CD25 + CD4 + T cell blasts, yet had little effect on MGAT5 expression ( Fig. 2g and Supplementary Fig. S2d ). sIL2RA reduced CTLA-4 surface levels in T cell blasts to a similar degree as anti-IL-2 neutralizing antibody ( Fig. 2e) . Directly comparing T cell blasts with or without the IL2RA*T risk allele revealed minimal differences in branching during early stages of activation; however by day 6, branching in IL2RA*TT and IL2RA*TC blasts was significantly reduced relative to IL2RA*CC blasts ( All variant haplotypes were less effective than the common haplotype, with those harbouring both the IV A (rs7726005) and V T − T (rs2070924 and rs2070925) polymorphisms reducing branching ~20%. The IV A and V T − T polymorphisms seem to exert additive effects, as separately each displayed a ~10% reduction in branching. Consistent with this, anti-CD3 and myelin-activated T cells heterozygous for the IV A and V T − T polymorphisms (hereafter referred as the MGAT1 IV A V T − T haplotype) displayed reduced upregulation of branching (Fig. 3b,c) . Transient transfection into Lec1 cells demonstrated that the IV A , V T − T and IV A V T − T haplotypes increased Mgat1 activity ~2-, 2-and 3-fold, respectively, a phenotype also associated with peripheral blood mononuclear cells (PBMCs) harbouring the MGAT1 IV A V T − T haplotype (Fig. 3d,e) . Matrix-assisted laser desorption/ionization-time of flight mass spectroscopy confirmed the N-glycan product of Mgat1 (mono-antennary) was increased relative to its N-glycan acceptor (Man 5 GlcNAc 2 ) in PBMCs with the MGAT1 IV A V T − T haplotype ( Fig. 3f and Supplementary Fig. S3d ).
The MGAT1 IV A V T − T haplotype harbours three polymorphisms in exon 2: an upstream non-synonymous coding single-nucleotide polymorphism (SNP; IV A : G1164A encoding Arg223Gln) and two synonymous coding SNPs that are ten nucleotides apart (V T − T : C1637T and G1648T). On the basis of the Mgat1 enzyme crystal structure, Arg223Gln is a surface-exposed residue far from the active site and therefore unlikely to effect enzyme activity 31 . However, IV A increased MGAT1 mRNA levels relative to the common haplotype in Lec1-transfected cells (Fig. 3g) . The two synonymous SNPs in V T − T , with or without IV A , also increased mRNA expression following transfection, although with differing kinetics. Analysis of heterozygous PBMCs confirmed mRNA levels of the MGAT1 IV A V T − T haplotype were ~2-fold higher than the common haplotype in vivo (Fig. 3h) .
The Km of Mgat5 for UDP-GlcNAc is significantly higher than Mgat1 (~11 versus ~0.04 mM), whereas this difference is reversed for their respective N-glycan acceptors (~0.087 versus ~2 mM) 15 . The ~2-to 3-fold increase in Mgat1 expression induced by the MGAT1 IV A V T − T haplotype increased Mgat1 product (Fig. 3f) while also reducing UDP-GlcNAc supply to downstream Mgat5. The latter is predicted to reduce β1,6GlcNAc branching by Mgat5, and indeed, this was observed both experimentally (Fig. 3a,b) and with computational modelling (Fig. 4a) 
15
. Thus, MGAT1 IV A V T − T functions dominantly to reduce branching under basal UDP-GlcNAc levels, but with increasing UDP-GlcNAc and/or Mgat5 levels, enhanced Mgat1 expression is expected to become less effective in limiting supply of UDP-GlcNAc to Mgat5, thereby allowing Mgat5 to act on the increased supply of N-glycan acceptors from Mgat1 to first equalize and then super-rescue β1,6GlcNAc branching. Indeed, these pathway dynamics were revealed by computational modelling (Supplementary Fig. S4a ) and confirmed experimentally by increasing UDP-GlcNAc levels in transiently transfected Lec1 cells and CD4 + T cells by GlcNAc supplementation (Fig. 4b and Supplementary Fig. S4b ). Consistent with this model, the magnitude of super-rescue by GlcNAc for the IV A , V T − T and IV A V T − T haplotypes was proportional to baseline enzyme activities. Thus, the gain-of-function haplotypes of MGAT1-reduce branching under basal conditions, but enhance levels when UDP-GlcNAc and/or Mgat5 are increased above a threshold.
Consistent with reduced branching, resting PBMCs heterozygous for the MGAT1 IV A V T − T haplotype were more sensitive to TCR agonist than cells homozygous for the common MGAT1 haplotype (Fig. 4c) . Blocking the branching with SW enhanced proliferation of cells with the common MGAT1 haplotype, but had little effect on cells heterozygous for the MGAT1 IV A V T − T haplotype, the latter consistent with the pre-existing deficiency in branching (Fig. 4c) .
The Thr17Ala polymorphism in human CTLA-4 encodes a nonsynonymous SNP (49A/G, rs231775) in the signal peptide that reduces average N-glycan occupancy at the two N-X-S/T sites from two to one, limiting CTLA-4 surface levels and promoting T cell proliferation 32, 33 . Such alterations in N-glycan number are expected to interact with the MGAT1 IV A V T − T haplotype to control CTLA-4 surface expression 15 . Indeed, computational modelling, co-transfection of Lec1 cells and analysis of T cell blasts confirmed previous observations 32, 33 of significantly lower surface CTLA-4 Ala17 (that is, one N-glycan) compared with CTLA-4 Thr17 (that is, two Nglycans) when co-expressed with the common MGAT1 haplotype ( Fig. 4d and Supplementary Fig. S4c-e) . The MGAT1 IV A V T − T haplotype also limited CTLA-4 surface levels when expressed with the common CTLA-4 Thr17 allele (two N-glycans) whereas combining the MGAT1 IV A V T − T haplotype with CTLA-4 Ala17 (one N-glycan) further reduced CTLA-4 surface levels. These phenotypes were rescued by increasing UDP-GlcNAc levels and/or GlcNAc supplementation, confirming that these phenotypes are sensitive to metabolism. GlcNAc also inhibited proliferation of T cells heterozygous for the MGAT1 IV A V T − T haplotype ( Supplementary Fig. S4f ).
Soluble receptors associated with the IL2RA*T and IL7RA*C MS risk alleles reduce Mgat1 mRNA and should interact with Mgat1 upregulation by the MGAT1 IV A V T − T haplotype to control branching (Fig. 4a) . Indeed, addition of exogenous IL-2 or IL-7 enhanced branching in control cells but reduced branching in MGAT1 IV A V T − T heterozygous cells (Fig. 4e , interaction P = 1.7×10 − 5 ). These results were predicted by computational modelling, with upregulation of Mgat1 by IL-2 or IL-7 enhancing or reducing branching depending on baseline Mgat1 activity (Fig. 4a) .
Taken together, these data indicate that the MGAT1 IV A V T − T haplotype lowers branching, T cell activation thresholds and CTLA-4 surface retention in a manner that is sensitive to metabolic conditions (that is, UDP-GlcNAc), activity of other Golgi branching enzymes (for example, Mgat5), the number of N-glycans attached to CTLA-4 (that is, CTLA-4 Thr17Ala) and IL-2 and IL-7 signalling.
Genetic interactions in MS.
The biological interactions defined above for IL2RA (rs2104286), IL7RA (rs6897932), MGAT1 IV A V T − T (rs7726005, rs2070924 and rs2070925) and CTLA-4 Thr17Ala (rs231775) are expected to result in genetic interaction in MS. To test this hypothesis, we first examined point association of the four variants in two Caucasian MS case-control cohorts from North America (n = 2,705 and n = 9,132, respectively). We replicated association of IL2RA (rs2104286) and IL7RA (rs6897932) as well as the lack of association of CTLA-4 (rs231775) in both cohorts (Table 1, Supplementary Table S1 ) 3, 22, 23, 34 . Although the MGAT1 IV A V T − T haplotype is relatively rare (carrier frequency ~7.2%), we observed a novel association for carrier status in both cohorts, with P = 1.51×10 − 5 and odds ratio (OR) = 1.36 in combined data of 3,280 cases and 8,557 controls (Table 1, Supplementary Table S1 ). Allelic analysis yielded a trend P value (Cochran-Armitage) of 1.90×10 − 5
(1 tail) for combined data. Pearson's correlation (r) confirmed that the IV A (rs7726005) and V T − T (rs2070924 and rs2070925) polymorphisms are in strong linkage disequilibrium (r = 0.633695, P < 2.2×10 − 16 ), as first observed by physical cloning and sequencing of genomic DNA (Fig. 3a) . Analysis of the IV A and V T-T polymorphisms irrespective of haplotype revealed association of V T-T (rs2070924 and rs2070925; P = 1.67×10 − 4 , OR = 1.29) and marginal association of IV A (rs7726005, P = 1.66×10 − 2 , OR = 1.13 (Supplementary Table S1)).
As gene-gene interaction analysis requires large sample sizes (power calculations in Table 1 ), especially when alleles are rare, we conducted stratified analysis in both Caucasian cohorts and interaction analyses only in combined data. Consistent with opposing effects on Mgat1 that optimize enzyme activity and branching when combined, stratified analysis of the Caucasian data reveals that MGAT1 IV A V T − T significantly increases MS risk when there are less than four copies of the IL2RA*T and IL7RA*C risk alleles (P = 3.60×10 − 5 , OR = 1.45), whereas no association was observed in the presence of four copies of the IL2RA*T and IL7RA*C (P = 0.195, OR = 1.13; Table 1, Supplementary Table S2 ). The P value for interaction is 6.75×10 (Table 1, Supplementary Table  S2 ). Stratifying the data based on six or less than six alleles of CTLA-4 Thr17, IL2RA*T and IL7RA*C strengthened the interaction, with MGAT1 IV A V T − T -promoting MS in the latter (P = 1.62×10 − 6 , OR = 1.46), whereas appearing to be protective in the former (P = 4.08×10 − 2 , OR = 0.64), giving an interaction P value of 9.48×10 − 4 . Finally, we examined an independent African-American MS cohort (758 cases, 480 controls). On the basis of HapMap data, IL2RA*T and IL7RA*C risk alleles are much more common in Sub-Saharan Africans/African-Americans (risk allele frequencies of ~0.90-0.95 versus ~0.75 in Caucasians). Indeed, analysis of a subset of the African-American MS cases (n = 478) revealed IL2RA*T and IL7RA*C allele frequencies of 0.94 and 0.88, respectively. As these high frequencies limit power, we restricted further analysis of the African-American cohort to MGAT1 IV A V T − T and CTLA-4 Thr17Ala. MGAT1 IV A V T − T did not display association in African-American MS (P = 0.215), with an OR similar to Caucasians with IL2RA*T + IL7RA*C = 4 (that is, 1.15 versus 1.13, respectively), a result consistent with the much higher frequencies of IL2RA*T and IL7RA*C in African-Americans (Table 1) . However, stratifying the data based on CTLA-4 Thr17Ala replicated the Caucasian MS data, with MGAT1 IV A V T − T -promoting MS in CTLA-4 Ala17 carriers (P = 8.40×10 − 3 , OR = 1.82), but appearing to be protective in CTLA-4 Thr/Thr homozygotes (P = 4.95×10 − 2 , OR = 0.64), with an interaction P value of 2.29×10 − 3 . The OR in CTLA-4 Thr/Thr homozygotes is similar to that in Caucasians with six alleles of CTLA-4 Thr17, IL2RA*T and IL7RA*C (that is, 0.64 and 0.64, respectively), again consistent with the much higher frequencies of IL2RA*T and IL7RA*C in AfricanAmericans. Combining the African-American and Caucasian P values gives P = 7.48×10 − 7 for CTLA-4 Ala17 carriers and P = 3.16×10 − 4 for interaction. Importantly, this interaction is observed despite lack of point association and marginal effects of CTLA-4 Thr17Ala in both the Caucasian and African-American data, indicating an epistatic interaction. Thus, the Caucasian and African-American MS data are concordant and when combined with the demonstrated biological interactions, provide strong evidence that the four variants converge on N-glycosylation to differentially regulate MS risk. CI, confidence intervals ; OR, odds ratio. Combined data from two independent North American Caucasian case-control MS cohorts and an African-American MS cohort. Reported is one-sided P values computed using the Cochran-Armitage test with MGAT1 IV A V T-T (rs7726005, r2070924 and rs2070925) coded 0 or 1 for carrier status and IL2RA*T (rs2104286), IL7RA*C (rs6897932) and CTLA-4 Thr17 (rs231775) coded as 0, 1 or 2 for the number of alleles. MGAT1 IV A V T-T homozygosity is 0.0016 and 0.0021 for Caucasian controls and MS, respectively. Compound heterozygosity for the IV A and V T-T variants is estimated at ~1 in 5,800 in Caucasians; therefore, subjects genotyped as heterozygous for both are treated as the MGAT1 IV A V T-T haplotype. All control cohorts are in Hardy-Weinberg Equilibrium.
Vitamin D 3 enhances Mgat1 to inhibit demyelinating disease.
Deficiency of vitamin D 3 , which is synthesized from 7-dehydrocholesterol in the skin on ultraviolet sun exposure, strongly associates with MS 2, 35, 36 . Vitamin D 3 and/or its active metabolite 1α,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) inhibit T cell activation 37 , interferon-γ production 38 and T cell-mediated demyelinating disease 38 ; however, molecular mechanisms are unclear. 1,25(OH) 2 D 3 enhanced MGAT1 mRNA levels in human male and female CD4 + CD25 + T cell blasts, a phenotype similar to the MGAT1 IV A V T − T haplotype but opposite of the IL2RA*T + IL7RA*C risk alleles (Fig. 5a ). 1,25(OH) 2 D 3 also increased MAN1A1, but had little effect on other Golgi branching genes. In the presence of the IL2RA*T and IL7RA*C risk alleles, 1,25(OH) 2 D 3 should enhance branching by reversing Mgat1 downregulation resulting from reduced IL-2 and IL-7 signalling. In contrast, upregulation of Mgat1 by 1,25(OH) 2 D 3 in T cell blasts lacking the IL2RA*T and IL7RA*C risk alleles is expected to have little or negative effect. Indeed, although 1,25(OH) 2 D 3 enhanced branching in T cell blasts with two or more copies of the IL2RA*T and IL7RA*C risk alleles (Fig. 5b) , branching was unchanged or reduced (depending on TCR stimulation strength) in blasting T cells homozygous for both protective alleles ( Fig. 5c and Supplementary Fig. S5 ). Addition of exogenous sIL2RA and sIL7RA to the latter cells, thereby mimicking the IL2RA*T and IL7RA*C risk alleles, restored the ability of 1,25(OH) 2 D 3 to enhance branching (Fig. 5c) . As a very small minority of Caucasians are homozygous for the IL2RA*C and IL7RA*T protective alleles (~0.5%), vitamin D 3 is expected to promote branching in the majority of the population. Fig. S6a,b) , whereas addition to TCR-activated female PL/J mouse T cells enhanced branching (Supplementary Fig. S6c ). Consistent with previous observations that 1,25(OH) 2 D 3 inhibits experimental autoimmune encephalomyelitis (EAE) in C57BL/6 female but not male mice, 1,25(OH) 2 D 3 had minimal effects on branching in male PL/J mouse T cell blasts ( Supplementary Fig. S6d) ; however, both male and female human T cell blasts responded similarly with enhanced branching (Supplementary Fig. S6e,f) . C57BL/6 mice are also deficient in Mgat1 activity, however, branching is reduced to a much smaller degree than PL/J mice 20 . Reducing dietary supply of vitamin D 3 in female PL/J mice decreased branching in CD4 + T cells in vivo in a dose-and time-dependent manner (Fig. 5d,e) . Intraperitoneal injection of 1,25(OH) 2 T cell blasts ( Fig. 6b and Supplementary Fig. S7a,b) and markedly reduced CTLA-4 endocytosis rates (Fig. 6c) . Intraperitoneal injection of 1,25(OH) 2 D 3 inhibited myelin basic protein (MBP)-induced EAE in PL/J female mice in the absence but not presence of SW in the drinking water (Fig. 6d) , where SW reduced branching in CD4 + T cells ~50% (Supplementary Fig. S7c ). SW also reversed 1,25(OH) 2 D 3 -induced hypoproliferation in MBP-stimulated T cells isolated from MBP-immunized PL/J mice (Fig. 6e) . Thus, vitamin D 3 promotes branching and CTLA-4 surface retention to suppress T cell growth and autoimmune demyelinating disease when Mgat1 activity is suppressed, as occurs with the IL2RA*T and IL7RA*C risk alleles and in the C57BL/6 and PL/J mouse strains.
Discussion
Defining how environmental factors combine with genetic risk at the molecular level to promote complex trait diseases such as MS has remained a great challenge. Here we suggest a unifying molecular mechanism in MS, whereby multiple environmental factors (sunlight/vitamin D 3 and metabolism) converge with multiple genetic variants (IL-7RA, IL-2RA, MGAT1 and CTLA-4) to dysregulate a final common pathway, Golgi N-glycosylation (Fig. 7) . A causal role for defective N-glycosylation is supported by the development of spontaneous inflammatory demyelination and neurodegeneration in Mgat1 and/or Mgat5-deficient mice 17, 20 , as well as the observed biological and genetic interactions that appear to differentially control N-glycosylation and MS risk. The ability of environmental factors such as vitamin D 3 /sunshine and/or metabolism to directly compensate for genetic downregulation of branching is consistent with concordance rates in monozygotic twins of only ~30% and their lack of significant detectable genomic, epigenomic or transcriptome differences 10, 11 . Therapeutic supplementation to N-glycan biosynthesis may serve as a simple therapy to suppress phenotypic expression of MS risk factors. Indeed, vitamin D 3 (1,25(OH) 2 D 3 ) and GlcNAc are orally active, rescue branching deficiency on mouse T cells in vivo and inhibit EAE and spontaneous autoimmune diabetes in mice 16, 38, 40 . In humans, oral GlcNAc improved disease in 8 of 12 children with treatment-resistant inflammatory bowel disease 41 .
Defective N-glycosylation likely promotes MS by multiple mechanisms. Reduced N-glycosylation lowers T cell activation thresholds and surface expression of the autoimmune inhibitor CTLA-4, promoting loss of self-tolerance. Mgat1 dysfunction may expose cryptic mannose linkages on the cell surface of oligodendrocytes that mimic microbial and pathogen glycans, chronically activating innate immune responses 42, 43 . Neurodegeneration in MS may arise from increased sensitivity to apoptotic stimuli. Indeed, targeted deficiency of Mgat1 in neurons induces their apoptosis in vivo, whereas Mgat5 deficiency enhances spontaneous neurodegeneration along with inflammatory demyelination 17, 20 . Thus, genetic and environmental alterations in the N-glycosylation pathway likely synergize to promote MS through dysfunction of both immune (T cells, antigen presenting cells) and target cells (oligodendrocytes, neurons).
IL2RA*T (rs2104286), IL7RA*C (rs6897932) and vitamin D 3 deficiency also associate with type 1 diabetes (T1D) 28, [44] [45] [46] , whereas non-obese diabetic mice are deficient for branching in T cells but not B cells 20 . A second independent variant of IL2RA (rs11594656) also alters sIL2RA levels and associates with both MS and T1D 28 , but paradoxically in opposite directions. CTLA-4 Ala17 (rs231775) displays point association with T1D but not MS 34, 47 . These considerations imply that defective N-glycosylation likely also contributes to T1D risk; however, interactions between these variants and MGAT1 IV A V T − T may differ because of disparity in CTLA-4 Ala17 (rs231775) frequencies between T1D and MS. Direct affects of branching deficiency on neuronal survival would also be expected to result in distinctive interactions in MS compared with T1D and other autoimmune diseases.
IL-7 and IL-2 both promote T cell growth, yet targeted deficiencies of these pathways in mice induce immunodeficiency and spontaneous autoimmunity, respectively 48, 49 . Our data suggest that by having opposing effects on branching in resting and activated T cells, IL-2 and IL-7 enhance T cell growth early by lowering branching and TCR activation thresholds but promote self-tolerance later by enhancing branching and CTLA-4 surface retention.
Before GWAS, many candidate gene studies proved unreliable. This failure likely arose from multiple issues such as very small sample size, lack of replication cohorts, poor selection of candidate genes (that is, no evidence for regulating spontaneous disease in animals) and association testing in the absence of detailed functional characterization. We avoided these issues by initially ignoring association testing and performing a detailed biological screen for functional variants that induce phenotypes causal of disease in mice. Critically, only the single variant with the greatest biological effect is selected for subsequent association testing in large cohorts. This reverse approach also avoids the problem of multiple hypothesis testing inherent to GWAS. Indeed, the P values we report (~10 − 5 to 10 − 7 ) are orders of magnitude better than the genome-wide significance level of ~5×10 − 8 that corrects to ~0.02 after adjusting for multiple hypothesis testing in a typical GWAS with ~550,000 SNPs 50 . 
